Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) Price Target at $40.67

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $40.67.

A number of equities analysts have issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th.

TG Therapeutics Stock Up 5.5 %

Shares of TGTX stock traded up $2.07 during trading hours on Friday, reaching $39.82. 4,483,390 shares of the company's stock were exchanged, compared to its average volume of 3,078,007. The stock has a market cap of $6.25 billion, a PE ratio of -398.16 and a beta of 2.30. TG Therapeutics has a 1 year low of $12.93 and a 1 year high of $43.32. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock's fifty day moving average price is $34.94 and its two-hundred day moving average price is $30.67.

Remove Ads

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. The firm had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. Research analysts predict that TG Therapeutics will post 0.08 EPS for the current year.

Insider Buying and Selling

In other news, CFO Sean A. Power sold 10,021 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 10.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TGTX. Vermillion Wealth Management Inc. acquired a new stake in TG Therapeutics during the fourth quarter worth approximately $30,000. Quadrant Capital Group LLC grew its position in shares of TG Therapeutics by 137.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after acquiring an additional 975 shares during the last quarter. Blue Trust Inc. boosted its stake in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 371 shares during the period. Smartleaf Asset Management LLC grew its position in TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 1,594 shares during the last quarter. Finally, Jones Financial Companies Lllp raised its holdings in TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 1,737 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.